Prognostic marker VPS72 could promote the malignant progression of prostate cancer

被引:2
作者
Xu, Xiaolong [1 ]
Wang, Wei [1 ]
He, Yi [1 ]
Yao, Yiqun [2 ]
Yang, Bo [1 ]
机构
[1] Dalian Med Univ, Dept Urol, Affiliated Hosp 2, 467,Zhongshan Rd, Dalian 116001, Liaoning, Peoples R China
[2] Dalian Univ, Dept Breast & Thyroid Surg, Affiliated Zhongshan Hosp, 6,Jiefang St, Dalian 116001, Liaoning, Peoples R China
关键词
Prostate cancer; VPS72; Clinical prognosis; Nomogram; STATISTICS; THERAPY;
D O I
10.1186/s12885-024-12488-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This paper attempted to clarify the role and mechanism of vacuolar protein sorting-associated protein 72 homolog (VPS72) in the progression of prostate cancer (PCa).Methods Clinical information and gene expression profiles of patients with prostate cancer were obtained from The Cancer Genome Atlas (TCGA). VPS72 expression in PCa and the potential mechanism by which VPS72 affects PCa progression was investigated. Next, we performed COX regression analysis to identify the independent prognostic factors of PCa, and constructed a nomogram. The sensitivity of chemotherapeutic medications was anticipated using "pRRophetic". Subsequently, in vitro assays to validate the effect of VPS72 on PCa cell proliferation, migration and susceptibility to anti-androgen therapy.Results The expression of VPS72 was considerably higher in PCa tissues compared to normal tissues. Significant correlations were found between high VPS72 expression and a poor prognosis and adverse clinicopathological factors. The nomogram model constructed based on VPS72 expression has good predictive performance. According to GSEA, VPS72-related genes were enriched in the NF-kB pathways, cytokine-cytokine receptor interaction and chemokine signaling pathway in PCa. Although PCa with low VPS72 expression was more adaptable to chemotherapeutic medications, our in vitro experiment showed that VPS72 knockdown significantly decreased the PCa cell migration, proliferation, and resistance to anti-androgen therapy.Conclusions In summary our findings suggests that VPS72 could play a crucial role in the malignant progression of PCa, and its expression level can be employed as a possible biomarker of PCa prognosis.
引用
收藏
页数:11
相关论文
共 22 条
  • [1] Metastatic Prostate Cancer: Treatment Options
    Achard, Verane
    Putora, Paul Martin
    Omlin, Aurelius
    Zilli, Thomas
    Fischer, Stefanie
    [J]. ONCOLOGY, 2021, : 48 - 59
  • [2] Secretory lysosomes
    Blott, EJ
    Griffiths, GM
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (02) : 122 - 131
  • [3] Vacuolar protein sorting-associated protein 72 homolog (VPS72) binding to lysine acetyltransferase 5 (KAT5) promotes the proliferation, invasion and migration of hepatocellular carcinoma through regulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway
    Chen, Tiejun
    Tu, Yinuo
    Lv, Dongnuo
    Lin, Kunpeng
    Tang, Hui
    Huang, Wenjie
    [J]. BIOENGINEERED, 2022, 13 (04) : 9197 - 9210
  • [4] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [5] Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
    Fizazi, Karim
    NamPhuong Tran
    Fein, Luis
    Matsubara, Nobuaki
    Rodriguez-Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    Sulur, Giri
    Luna, Yesenia
    Li, Susan
    Mundle, Suneel
    Chi, Kim N.
    [J]. LANCET ONCOLOGY, 2019, 20 (05) : 686 - 700
  • [6] Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer - Eastern Cooperative Oncology Group study PH882
    Haas, NB
    Manola, J
    Hudes, G
    Citrin, DL
    Kies, MS
    Davis, TE
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (06): : 589 - 592
  • [7] Genomic and phenotypic heterogeneity in prostate cancer
    Haffner, Michael C.
    Zwart, Wilbert
    Roudier, Martine P.
    True, Lawrence D.
    Nelson, William G.
    Epstein, Jonathan, I
    De Marzo, Angelo M.
    Nelson, Peter S.
    Yegnasubramanian, Srinivasan
    [J]. NATURE REVIEWS UROLOGY, 2021, 18 (02) : 79 - 92
  • [8] Bioinformatics Analysis and RNA-Sequencing of SCAMP3 Expression and Correlated Gene Regulation in Hepatocellular Carcinoma
    Han, Shan-shan
    Feng, Zhi-qiang
    Liu, Rui
    Ye, Jun
    Cheng, Wei-wei
    Bao, Jun-bo
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 1047 - 1057
  • [9] Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
    Harris, William P.
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Montgomery, Bruce
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2009, 6 (02): : 76 - 85
  • [10] VPS72, a member of VPS protein family, can be used as a new prognostic marker for hepatocellular carcinoma
    Huang, Jian
    Gan, Jin
    Wang, Jian
    Zheng, Min
    Xiao, Han
    [J]. IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (05)